ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.
Industry, Sector and Symbol
Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolTSE:EPI
Previous Symbol
CUSIPN/A
Phone+1-778-3310962
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00
OptionableOptionable
ESSA Pharma (TSE:EPI) Frequently Asked Questions
What is ESSA Pharma's stock symbol?
ESSA Pharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "EPI."
Has ESSA Pharma been receiving favorable news coverage?
Media coverage about EPI stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ESSA Pharma earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the stock's share price in the next few days.
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the folowing people:
- Richard M. Glickman LL.D., Chairman of the Board (Age 57)
- David Ross Parkinson M.D., President, Chief Executive Officer, Director (Age 67)
- David Wood, Chief Financial Officer (Age 57)
- Peter Virsik, Chief Operating Officer, Executive Vice President
- Raymond L. Andersen, Chief Technology Officer, Director (Age 67)
- Marianne D. Sadar, Chief Scientific Officer, Director (Age 53)
- Frank Perabo, Chief Medical Officer (Age 50)
- Franklin M. Berger, Director (Age 67)
- Scott Requadt J.D., Director
- Gary Sollis, Director (Age 61)
How do I buy shares of ESSA Pharma?
Shares of EPI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ESSA Pharma's official website?
How can I contact ESSA Pharma?
ESSA Pharma's mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-778-3310962.
MarketBeat Community Rating for ESSA Pharma (TSE EPI)
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
